EU agency has no new concerns about incretin diabetes drugs

Current data do not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency.

Source: theHeart.org - July 26, 2013 Category: Cardiology Source Type: news